Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...

“High quality, large-scale, fit-for-purpose datasets” continues to be the tagline for artificial intelligence (AI) models aiming to achieve scalable drug discovery to novel targets. While troves of ...

Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

Platform now available to pharmaceutical research partners; powers collaborations totaling over $200 million SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Variant Bio, a genomics-driven AI drug discovery ...

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug ...

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...